AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 23169194
Drug: Verified prescription
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verified prescription using probe‐microphone measurement
Trial: 23169194
Drug: Verified prescription
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verified prescription
Trial: 20089954
Drug: Oral fingolimod
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral fingolimod 1.25 mg
Trial: 20089954
Drug: Oral fingolimod
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral fingolimod 0.5 mg
Trial: 20167591
Drug: Intramuscular interferon
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular interferon beta-1a
Trial: 18931224
Drug: High-dose antithrombin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose antithrombin (30,000 IU IV over 4 days)
Trial: 18931224
Drug: High-dose antithrombin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose antithrombin
Trial: 11495875
Drug: 3 mg
RxNorm normalized name: boron 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg of intrathecal ropivacaine (group R)
Trial: 11495875
Drug: 3 mg
RxNorm normalized name: boron 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg ropivacaine with 10 microg of sufentanil (group RS)
Trial: 9759744
Drug: H. pylori
RxNorm normalized name: H. PYLORI AGENTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H. pylori eradication treatment (omeprazole 20 mg, amoxycillin 1000 mg, and clarithromycin 500 mg, twice daily for 1 week)
Trial: 9759744
Drug: Control treatment
RxNorm normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control treatment (omeprazole with placebo antibiotics)
Trial: 28473006
Drug: Watermemories Swimming
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Watermemories Swimming Club aquatic exercise program (12 weeks, twice weekly)
Trial: 20926529
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human GH (0.64 mg/d)
Trial: 9146855
Drug: Inhaled salbutamol
RxNorm normalized name: salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Inhaled salbutamol (600 micrograms)
Trial: 7711007
Drug: Glucose (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose (100 g in 400 ml) administered 30 min before tests
Trial: 7711007
Drug: Water (equal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Water (equal volume to glucose) administered 30 min before tests
Trial: 30538005
Drug: G:G genotype
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G:G genotype
Trial: 25439692
Drug: Dacomitinib 45
RxNorm normalized name: dacomitinib 45 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dacomitinib 45 mg once-daily
Trial: 23044290
Drug: Anisodamine infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Anisodamine infusion at a rate of 0.2 µg×kg(‐1)×min(‐1) from 12 hours before to 12 hours after coronary angiography or angioplasty
Trial: 23044290
Drug: Sodium chloride
RxNorm normalized name: Sodium Chloride
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium chloride infusion (control group)
Trial: 23044290
Drug: Anisodamine infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Anisodamine infusion
Trial: 18839224
Drug: MESNA (Uromixetan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MESNA (Uromixetan MESNA, 50 mg/ml)
Trial: 14500050
Drug: Treatment A
RxNorm normalized name: Nix Ultra Lice Treatment And Prevention Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment A (initially allocated in a 1:1 ratio)
Trial: 14500050
Drug: Treatment B
RxNorm normalized name: PanOxyl Acne Treatment Bar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment B (initially allocated in a 1:1 ratio)
Trial: 14500050
Drug: Group sequential
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group sequential design
Trial: 6701925
Drug: Reduced-dose irradiation
RxNorm normalized name: Iron, reduced
DrugBank: Iron (DB01592)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reduced-dose irradiation and subsequent simultaneous combination of polychemotherapy and irradiation
Trial: 12474066
Drug: Tomato juice
RxNorm normalized name: TOMATO JUICE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tomato juice (330 mL daily for 8 weeks)
Trial: 9841956
Drug: Sodium citrate
RxNorm normalized name: Sodium Citrate
DrugBank: Sodium nitrate (DB15952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium citrate solution (0.3 g x kg‐1 body mass)
Trial: 7806684
Drug: Haloperidol 20
RxNorm normalized name: haloperidol 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol 20 mg
Trial: 7806684
Drug: Haloperidol 30
RxNorm normalized name: Haloperidol 300 microgram/mL oral solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol 30 mg
Trial: 2760092
Drug: Repair and
RxNorm normalized name: Pantene Repair And Protect Shampoo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repair and augmentation of the anterior cruciate ligament with a strip of the iliotibial band
Trial: 28505233
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of dexamethasone (DEX), ondansetron (OND), and droperidol (DRO) (Group B)
Trial: 28505233
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of dexamethasone (DEX) and ondansetron (OND) (Group A)
Trial: 22433304
Drug: ETV 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ETV 1.0 mg/d monotherapy
Trial: 22433304
Drug: ETV +
RxNorm normalized name: Entecavir
DrugBank: Entecavir (DB00442)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ETV + ADV 10 mg/d
Trial: 19454403
Drug: SGS (structured
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SGS (structured diabetes teaching and treatment programme)
Trial: 12601511
Drug: Pelvicol( trademark
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pelvicol( trademark ) implant
Trial: 8724378
Drug: Hypertonic glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypertonic glucose solution (Group I)
Trial: 3927062
Drug: Group II
RxNorm normalized name: Platelet group IIa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group II - Specially formulated amino acid solution with glucose and fructose
Trial: 29317275
Drug: Dose increases
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose increases (2 maximum) in steps of 2.5 mg/kg based on clinical symptoms and biomarker analysis and/or serum infliximab concentrations (DIS1 group)
Trial: 29317275
Drug: Dose increase
RxNorm normalized name: Incruse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose increase from 5 to 10 mg/kg based on the same criteria (DIS2 group)
Trial: 29317275
Drug: Dose increase
RxNorm normalized name: Incruse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose increase to 10 mg/kg based on clinical symptoms alone (control group)
Trial: 25511449
Drug: POLD technique
RxNorm normalized name: poldine
DrugBank: Poldine (DB13507)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: POLD technique (manual oscillatory therapy)
Trial: 19141980
Drug: Group C
RxNorm normalized name: STREPTOCOCCUS ANTIGEN (GROUP C)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group C (rabeprazole, amoxicillin, and furazolidone)
Trial: 19141980
Drug: Group D
RxNorm normalized name: Prostaglandin group D
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group D (ranitidine bismuth citrate, amoxicillin, and furazolidone)
Trial: 16185755
Drug: MVAC (methotrexate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MVAC (methotrexate 30 mg/m2 IV days 1, 15, and 22, vinblastine 3 mg/m2 IV days 2, 15, and 22, doxorubicin 30 mg/m2 IV day 2, cisplatin 70 mg/m2 day 2 of a 4-week cycle)
Trial: 16185755
Drug: AC (doxorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AC (doxorubicin 30 mg/m2 + cisplatin 70 mg/m2 IV q 4 weeks)
Trial: 11215835
Drug: 50/50 titration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50/50 titration schedule (initial dosage 50 mg/d increased in 50 mg/d increments at weekly intervals)
Trial: 11215835
Drug: 100/200 titration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100/200 titration schedule (initial dosage 100 mg/d increased by 100-200 mg/d at weekly intervals)
Trial: 9034229
Drug: CaP/P tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CaP/P tablet formulation
Trial: 9034229
Drug: CaP/GG tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CaP/GG tablet formulation
Trial: 8515293
Drug: Piperacillin (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piperacillin (2 g i.v. single dose)
Trial: 3027841
Drug: Itraconazole 100
RxNorm normalized name: itraconazole 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Itraconazole 100 mg daily for five days (women)
Trial: 31044654
Drug: Routine medical
RxNorm normalized name: Peace Out Acne Hero Routine KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine medical treatment (Control Group)
Trial: 25362247
Drug: Intraarticular hyaluronic
RxNorm normalized name: hyaluronate
DrugBank: Hyaluronic acid (DB08818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intraarticular hyaluronic acid injections combined with a single local injection of corticosteroid-lidocaine (Group 2)
Trial: 25362247
Drug: Intraarticular hyaluronic
RxNorm normalized name: hyaluronate
DrugBank: Hyaluronic acid (DB08818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intraarticular hyaluronic acid injections only (Group 1)
Trial: 24639149
Drug: Ferumoxytol (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ferumoxytol (two doses of 510 mg 5 ± 3 days apart)
Trial: 24639149
Drug: Iron sucrose
RxNorm normalized name: Iron Sucrose
DrugBank: Iron sucrose (DB09146)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron sucrose (five doses of 200 mg on five nonconsecutive days over 14 days)
Trial: 23967637
Drug: Staging treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Staging treatment group (acupuncture at tendon points, electric thermal needling, small needle-knife therapy, bleeding method, electric thermal therapy with thick silver needles)
Trial: 12482554
Drug: DHA (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHA (4 g/day)
Trial: 12482554
Drug: EPA (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EPA (4 g/day)
Trial: 8403674
Drug: Local antibiotics
RxNorm normalized name: RECTAL,LOCAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local antibiotics (Septopal) alone
Trial: 8403674
Drug: Conventional antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional antibiotics or combined treatment
Trial: 2883060
Drug: 25 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 micrograms SMS 201-995 twice daily
Trial: 31584341
Drug: Treatment of
RxNorm normalized name: DRUGS FOR TREATMENT OF LEPRA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment of distal radial fractures
Trial: 27287207
Drug: Bevacizumab treatment
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab treatment (n = 179)
Trial: 24974131
Drug: Metformin (Arm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (Arm B; n = 6)
Trial: 24974131
Drug: Per protocol
RxNorm normalized name: Olay Professional Acne Protocol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Per protocol analysis for Metformin (Arm B)
Trial: 20549525
Drug: Interpersonal psychotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interpersonal psychotherapy treatment for postpartum depression
Trial: 20590369
Drug: Acoustic wave
RxNorm normalized name: aconite
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acoustic wave therapy (AWT) using extracorporeal pulse activation technology (EPAT)
Trial: 16324360
Drug: Routine treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine treatment with fluid resuscitation and wound management, normal saline IV drop bid for 7 days
Trial: 8018759
Drug: Conventional serum
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional serum therapy
Trial: 11739866
Drug: Dietary diacylglycerol
RxNorm normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dietary diacylglycerol (DG) oil (target dose 10 g/d) for 12 weeks
Trial: 22364141
Drug: lopinavir/ritonavir (LPV/r)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lopinavir/ritonavir (LPV/r) 400/100 mg BID + raltegravir (RAL) 400 mg BID
Trial: 20163864
Drug: Bimatoprost gel
RxNorm normalized name: Bimatoprost
DrugBank: Bimatoprost (DB00905)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Bimatoprost gel suspension applied to the base of the eyelashes every evening for 6 weeks
Trial: 20163864
Drug: Placebo (normal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (normal saline gel suspension) applied to the base of the eyelashes every evening for 6 weeks
Trial: 16006724
Drug: Rosiglitazone 2
RxNorm normalized name: rosiglitazone 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosiglitazone 2 mg/day
Trial: 17203469
Drug: Eptifibatide (GP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eptifibatide (GP IIb/IIIa inhibitor)
Trial: 6269234
Drug: Ranitidine (follow-up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine (follow-up after initial treatment)
Trial: 6269234
Drug: Placebo (follow-up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (follow-up after initial treatment)
Trial: 31839104
Drug: Docetaxel plus
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel plus cisplatin preoperative neoadjuvant chemotherapy (Group A)
Trial: 31839104
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment after preoperative examination (Group B)
Trial: 28711708
Drug: Ezetimibe and
RxNorm normalized name: Ezetimibe and Simvastatin Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ezetimibe and simvastatin combination
Trial: 22447014
Drug: Combination pill
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination pill (losartan 50mg/hydrochlorothiazide 12.5mg)
Trial: 22447014
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (angiotensin receptor blocker and thiazide diuretic)
Trial: 17524942
Drug: MMF 500
RxNorm normalized name: MMF
DrugBank: Monomethyl fumarate (DB14219)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MMF 500 (500 mg single oral dose)
Trial: 17524942
Drug: CellCept (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CellCept (500 mg single oral dose)
Trial: 11986597
Drug: Intraoperative intrapleural
RxNorm normalized name: INTRAPLEURAL MEDICATIONS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraoperative intrapleural hypotonic cisplatin treatment (50 microg/mL in distilled water for 15 minutes)
Trial: 2699994
Drug: Calcitriol (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcitriol (0.25 to 0.5 micrograms daily)
Trial: 603844
Drug: Duogastrone (carbenoxolone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duogastrone (carbenoxolone sodium) 50 mg qid for 6 weeks
Trial: 603844
Drug: Placebo capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules qid for 6 weeks
Trial: 29243795
Drug: Recombinant LH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant LH (r‐LH) added to recombinant FSH (r‐FSH) in the late follicular phase starting the same day of GnRH-antagonist administration.
Trial: 17623719
Drug: 1.3 g
RxNorm normalized name: glycerin 1.3 g RECTAL SUPPOSITORY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.3 g of EPA + DHA daily
Trial: 15154664
Drug: Chemotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy with CMF regimens and radiotherapy before 90 days after surgery
Trial: 15154664
Drug: Chemotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy with CMF regimens and radiotherapy after 90 days after surgery
Trial: 11402634
Drug: Gastric-retentive extended-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gastric-retentive extended-release metformin hydrochloride tablets
Trial: 11402634
Drug: Immediate-release metformin
RxNorm normalized name: metformin Extended Release Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate-release metformin hydrochloride product
Trial: 8582130
Drug: Control meal
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control meal (no drug)
Trial: 2172884
Drug: Chemotherapy and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy and radiotherapy of 30 Gy
Trial: 2172884
Drug: Chemotherapy and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy and radiotherapy of 50 Gy
Trial: 2172884
Drug: All groups
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All groups (30 Gy, 50 Gy, and chemotherapy alone)
Trial: 720236
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 75 mg dipyridamol and 330 mg acetylsalicylic acid, three times daily by mouth
Trial: 720236
Drug: Acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetylsalicylic acid alone at the same dosage
Trial: 28100203
Drug: VR exposure
RxNorm normalized name: Prostin VR
DrugBank: Alprostadil (DB00770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: VR exposure treatment with diaphragmatic breathing (six cycles per minute)
Trial: 28100203
Drug: VR exposure
RxNorm normalized name: Prostin VR
DrugBank: Alprostadil (DB00770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: VR exposure treatment without diaphragmatic breathing
Trial: 19474138
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg ferrous sulfate
Trial: 17276712
Drug: Montelukast (5mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Montelukast (5mg chewable tablet once daily for 8 weeks)
Trial: 15191819
Drug: Intramuscular dissection
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramuscular dissection of perforators (DIEP flap)
Trial: 10954759
Drug: 0.625 mg
RxNorm normalized name: estrone 0.625 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.625 mg of conjugated estrogen per day
Trial: 10954759
Drug: 0.625 mg
RxNorm normalized name: estrone 0.625 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.625 mg of conjugated estrogen plus 2.5 mg of medroxyprogesterone acetate per day
Trial: 9077373
Drug: Alcohol consumption
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alcohol consumption (more than 800 g pure ethanol annually)
Trial: 9077373
Drug: Low HDLc
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low HDLc (mean 0.94 mmol L‐1)
Trial: 9077373
Drug: Normal HDLc
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal HDLc (mean 1.25 mmol L‐1)
Trial: 25262788
Drug: niosomal methylene
RxNorm normalized name: Methylene Blue
DrugBank: Methylene blue (DB09241)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: niosomal methylene blue (NMB) gel
Trial: 25262788
Drug: unloaded (free)
RxNorm normalized name: acid red 337 free acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: unloaded (free) methylene blue (FMB) gel
Trial: 9539056
Drug: Diclofenac monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofenac monotherapy
Trial: 9539056
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment with Tramadol-retard and Naproxen
Trial: 2510677
Drug: APSAC (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: APSAC (30 IU) administered by intravenous bolus injection over 2 to 5 minutes
Trial: 2510677
Drug: Streptokinase (SK)
DrugBank: Streptokinase (DB00086)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Streptokinase (SK) (1.5 million IU) administered by intravenous infusion over 60 minutes
Trial: 803252
Drug: Adjuvant MOPP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant MOPP chemotherapy with irradiation
Trial: 803252
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment (Adjuvant MOPP chemotherapy with irradiation)
Trial: 803252
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (without adjuvant MOPP chemotherapy)
Trial: 21762268
Drug: PBMT7 (pantoprazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PBMT7 (pantoprazole 40 mg twice daily, metronidazole 500 mg thrice daily, bismuth subcitrate 300 mg and tetracycline 500 mg four times daily for 7 days)
Trial: 21762268
Drug: PBMT14 (pantoprazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PBMT14 (pantoprazole 40 mg twice daily, metronidazole 500 mg thrice daily, bismuth subcitrate 300 mg and tetracycline 500 mg four times daily for 14 days)